All News
Filter News
Found 7,634 articles
-
Protalix Biotherapeutics, Inc. Announces New Strategy For Accelerated Growth
1/5/2015
-
Hospira, Inc. Receives U.S. FDA Approval Of Proprietary Analgesic Dyloject™(diclofenac sodium) Injection
12/30/2014
-
Palatin Technologies Announces Start Of Bremelanotide Phase 3 Program For Female Sexual Dysfunction
12/29/2014
-
Hospira, Inc. Announces Voluntary Worldwide Recall Of 10 Lots Of Mitoxantrone Due To Confirmed Subpotency And Out-Of-Specification Impurities
12/24/2014
-
Baxter International, Inc. Submits Application For U.S. FDA Approval Of BAX111, Investigational Recombinant Treatment For Von Willebrand Disease
12/22/2014
-
Pfenex Inc. Announces Active IND And Additional BARDA Funding For Recombinant Anthrax Vaccine Program, Px563L
12/22/2014
-
Hospira, Inc. To Present At The J.P. Morgan 33rd Annual Healthcare Conference Jan. 14, 2015
12/22/2014
-
Creative Diagnostics Launches Improved Biosimilar Stable Cell line Products
12/18/2014
-
Apotex Inc. Announces FDA Has Accepted For Filing Its Biosimilar Application For Pegfilgrastim
12/17/2014
-
ImmunXperts Successfully Raises In Excess Of 1 Million USD In Equity And Bank Financing
12/17/2014
-
Actavis Will Appeal Injunction Requiring Continued Distribution Of NAMENDA IR
12/16/2014
-
Coherus Biosciences Reports Third Quarter 2014 Financial And Operating Results
12/16/2014
-
Actavis Announces Proposed Senior Leadership Team Effective Following Completion Of Allergan Acquisition
12/16/2014
-
Baxter International, Inc. To Divest Vero Cell Vaccines Platform To Nanotherapeutics
12/15/2014
-
Gene Therapy to Cure Blindness in 2015? Biotech Predictions Revealed
12/12/2014
-
Cipla Ltd. Sells Stake In Jiangsu Cdymax Pharma For $18.5 Million
12/12/2014
-
EPIRUS Biopharmaceuticals Seeks British Columbia Securities Commission Order That It Is No Longer A Reporting Issuer
12/12/2014
-
Zydus Cadila Launches World's First Biosimilar Of AbbVie's Humira In India
12/9/2014
-
Novartis AG Copy Of Amgen Cancer Drug Shows Similar Efficacy
12/8/2014
-
Phase 3 Data Shows Sandoz, Inc.'s Investigational Biosimilar Filgrastim Has Similar Safety And Efficacy As Amgen's NEUPOGEN®
12/8/2014